Groundbreaking Study Shows Cost-Effectiveness of Neuroimmune Modulation Therapy for Rheumatoid Arthritis Treatment

Overview of the Study

SetPoint Medical recently published a critical peer-reviewed study in the Journal of Medical Economics, shedding light on the cost-effectiveness of its SetPoint System®, a neuroimmune modulation device approved by the FDA. This innovative therapy aims to treat adults suffering from moderate to severe rheumatoid arthritis (RA), a chronic autoimmune disease affecting millions of Americans. The study's findings illuminate the potential of the SetPoint System to significantly reduce healthcare costs while enhancing the quality of life for RA patients.

Major Findings

The analysis utilized a decision-analytic Markov model to evaluate the cost-effectiveness of neuroimmune modulation therapy over various time horizons: two years, ten years, and a patient's lifetime. The clinical data came from the RESET-RA pivotal trial, which led to the FDA’s approval of the SetPoint System.

1. Cost Recovery: One of the most striking results showed that the initial costs for the device and the procedure could be recouped in less than 16 months.
2. Economic Dominance: The study revealed that neuroimmune modulation therapy results in substantial savings—specifically $25,397 after two years, $197,062 after ten years, and a remarkable $350,052 over a patient's lifetime. This positions it as an economically dominant treatment strategy.
3. Consistent Effectiveness: Across different sensitivity analyses, the therapy maintained its cost-effective nature, proving valid even when adjusting for lower drug costs or increased drug pairing with the SetPoint Therapy.

Implications for Patients

The impact of RA can be devastating, with over 1.5 million individuals grappling with the disease in the U.S. alone. Traditional treatment methods involving biological and targeted therapies account for nearly $30 billion in spending annually. SetPoint's device-based alternative offers a non-pharmacological approach that activates anti-inflammatory pathways through daily vagus nerve stimulation. The results suggest that this method not only optimizes treatment effectiveness but also offers significant financial benefits to the healthcare system.

The Future of RA Treatment

Murthy Simhambhatla, CEO of SetPoint Medical, expressed optimism about the implications of these findings for future arthritis care. He emphasized the transformative potential of neuroimmune modulation in establishing a new standard of care for RA patients. The SetPoint System was FDA-approved in July 2025 and is set to expand its reach throughout 2026, paving the way for broader patient access across the U.S.

Conclusion

This landmark study highlights the importance of sustainable healthcare solutions that balance clinical benefits with economic value, presenting a compelling case for the integration of neuroimmune modulation therapy in rheumatoid arthritis treatment protocols. With ongoing evaluations and research into additional applications for multiple autoimmune conditions such as multiple sclerosis and Crohn's disease, SetPoint Medical is poised to revolutionize the landscape of chronic disease management.

For more detailed insights, the full study is accessible in the Journal of Medical Economics, which specializes in high-quality assessments of new therapeutic and device interventions. The findings promise to reshape not just treatment strategies but also economic frameworks surrounding chronic disease therapy in the healthcare sector.